assay to help monitor response to treatment in malignant mesothelioma
patients. The MESOMARK test signifies the beginning of a early era in
monitoring mesothelioma malignancies," said Dr. W. Jeffrey Allard,
vice president and chief scientific officer of Fujirebio Diagnostics.
"As the first in-vitro test for patients with this aggressive disease,
it'll enable doctors to more accurately recognise recurrence and
monitor treatment of patients."The MESOMARK Assay test kit was
developed to measure levels of a biomarker, mesothelin, in serum.
Biomarkers are substances found in higher-than-normal concentrations
in the blood, urine or body tissues of patients with definite types of
cancers. The test might be used to monitor patients confirmed as
having mesothelioma, for recurrence in patients following surgery, or
for measuring response to therapies.
"Current diagnostic tests are less than ideal for quantification of
modifies in tumor volume, which is key to managing the disease,"
continued Allard. "As the MESOMARK results correlate with tumor
volume*, it give s a much needed tool for monitoring patient status.
It is our plan to collect additional data in the future to back up the
use of the test to detect mesothelioma."
MESOMARK test are now making it achievable - with a simple blood test
-to monitor response to treatment and to detect recurrence following
treatment. This provides an important head initiate to patients racing
against this aggressive cancer. "The Meso Foundation is the national
research funding, patient support and advocacy organization dedicated
to eradicating mesothelioma as a life-threatening disease.
Those wishing to take part in MESOMARK testing will be asked to
provide one or more samples of blood. The blood samples will then be
sent to a national reference laboratory for testing. In conjunction
with different clinical and laboratory data obtained by your doctor,
decisions regarding your treatment and concern may be simplified. You
may discontinue testing at any time.
No comments:
Post a Comment